Modified CEA nucleic acid and expression vectors
View Patent ↗The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
1. A method for preventing or treating a CEA antigen expressing cancer in a host comprising administering to the host an isolated expression vector comprising SEQ ID NO:28.
2. The method of claim 1 wherein the vector is a plasmid or a viral vector.
3. The method of claim 2 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
4. The method of claim 3 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
5. The method of claim 1 , wherein the expression vector further comprises a nucleic acid sequence encoding a co-stimulatory molecule.
6. The method of claim 5 , wherein the co-stimulatory molecule is human B7.1.
7. The method of claim 1 , wherein the expression vector further comprises a nucleic acid sequence encoding at least one additional tumor-associated antigen.
8. The method of claim 1 , wherein the expression vector further comprises a nucleic acid sequence encoding at least one angiogenesis-associated antigen.
9. The method of claim 1 wherein the expression vector is admixed with a pharmaceutically acceptable carrier.
10. A method for preventing or treating a CEA antigen expressing cancer in a host comprising administering to the host an isolated expression vector comprising a CEA-encoding nucleic acid sequence including at least the sequence set forth by 421-1490 of SEQ ID NO:28.
11. The method of claim 10 wherein the vector is a plasmid or a viral vector.
12. The method of claim 11 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
13. The method of claim 12 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
14. The method of claim 10 , wherein the expression vector further comprises a nucleic acid sequence encoding a co-stimulatory molecule.
15. The method of claim 14 , wherein the co-stimulatory molecule is human B7.1.
16. The method of claim 10 , wherein the expression vector further comprises a nucleic acid sequence encoding at least one additional tumor-associated antigen.
17. The method of claim 10 , wherein the expression vector further comprises a nucleic acid sequence encoding at least one angiogenesis-associated antigen.
18. The method of claim 10 wherein the expression vector is admixed with a pharmaceutically acceptable carrier.